The Effect of Lactobacillus reuteri on Regional Gene Expression in Type 1 Diabetic Mice Intestine
As of 2014, 1.45 million Americans were diagnosed with type 1 diabetes, a disease that results in the inability to produce insulin. The resulting altered metabolism can lead to many complications including bone loss. This research was conducted in pursuit of a potential treatment utilizing the probiotic, Lactobacillus reuteri (L. reuteri) to bone loss caused by Type 1 diabetes. Previous research has shown a relationship between the gut health and bone health; where the excretion of varying levels of hormones, proteins and cytokines from the gut effects bone health.[2-4] For example, gut inflammation can effect bone formation and resorption. In this study, RNA was extracted from intestinal sections obtained from control and diabetic mice treated with or without L. reuteri to assess the effects of diabetes and probiotic treatment on regional gene expression. Results of RT-PCR analyses show that L. reuteri treatment can affect diabetes induced changes in intestinal gene expression, including decreasing the expression of TNF-α in the colon and the increase in the expression of TNF-α in both the jejunum and ileum. Further studies need to be performed to confirm if L. reuteri can serve as a therapeutic treatment for Type 1 diabetes and its complications.